Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant

Rhea-AI Filing Summary

Vera Therapeutics director Beth C. Seidenberg received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided she continues in service. They also fully vest if there is a change in control while she remains in service through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SEIDENBERG BETH C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,084	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 17,084 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 17,084 options Exercise price: $34.35 per share Underlying shares: 17,084 shares +2 more

5 metrics

Options granted 17,084 options Stock Option (right to buy) granted to director

Exercise price $34.35 per share Exercise price for Class A common stock underlying options

Underlying shares 17,084 shares Class A common stock underlying the option award

Expiration date May 20, 2036 Option expiration for director grant

Post-grant derivative holdings 17,084 options Total derivative securities following the reported transaction

Key Terms

Stock Option (right to buy), Class A Common Stock, exercise price, change in control, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: 34.3500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"shares will vest in full upon a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEIDENBERG BETH C

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$34.35	05/21/2026		A		17,084		(1)	05/20/2036	Class A Common Stock	17,084	$0	17,084	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

	/s/ Joseph R. Young, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Vera Therapeutics (VERA) director Beth Seidenberg report in this Form 4?

Beth C. Seidenberg reported receiving a stock option grant for 17,084 shares of Vera Therapeutics Class A common stock. The options are a compensation award, not an open-market purchase or sale, and give her the right to buy shares at a fixed exercise price.

How many Vera Therapeutics (VERA) shares are covered by the new option grant?

The grant covers options on 17,084 shares of Vera Therapeutics Class A common stock. This entire amount was acquired in a single award and represents her total derivative holdings following the reported transaction in this filing.

What is the exercise price and expiration date of Beth Seidenberg’s Vera Therapeutics options?

The stock options have an exercise price of $34.35 per share and expire on May 20, 2036. She can choose to exercise them any time after they vest and before this expiration date, subject to the plan’s terms.

When do Beth Seidenberg’s Vera Therapeutics stock options vest?

The options vest in full on the earlier of the first anniversary of the grant date or Vera Therapeutics’ 2027 annual stockholder meeting. Vesting is conditioned on her continuous service with the company through the relevant vesting date.

What happens to Beth Seidenberg’s options if Vera Therapeutics undergoes a change in control?

If Vera Therapeutics experiences a change in control, the stock options vest in full at that time, provided Beth Seidenberg remains in continuous service through the change in control date. This accelerates vesting compared with the normal schedule.

Is this Vera Therapeutics (VERA) Form 4 a market purchase or sale of shares?

No, this Form 4 reports a compensation-related grant of stock options, not an open-market transaction. The reporting person did not buy or sell existing shares in the market; she received options giving a future right to purchase shares.